Mitogen-activated protein kinase proteins regulate LPS-stimulated release of pro-inflammatory cytokines and prostaglandins from human gestational tissues

Lappas, M., Permezel, M. and Rice, G. E. (2007) Mitogen-activated protein kinase proteins regulate LPS-stimulated release of pro-inflammatory cytokines and prostaglandins from human gestational tissues. Placenta, 28 8-9: 936-945. doi:10.1016/j.placenta.2007.02.009


Author Lappas, M.
Permezel, M.
Rice, G. E.
Title Mitogen-activated protein kinase proteins regulate LPS-stimulated release of pro-inflammatory cytokines and prostaglandins from human gestational tissues
Journal name Placenta   Check publisher's open access policy
ISSN 0143-4004
1532-3102
Publication date 2007-08-01
Sub-type Article (original research)
DOI 10.1016/j.placenta.2007.02.009
Volume 28
Issue 8-9
Start page 936
End page 945
Total pages 10
Place of publication Oxford, United Kingdom
Publisher Elsevier
Language eng
Formatted abstract
The role of pro-inflammatory cytokines and prostaglandins in human labour is well established. Many of the mRNAs stabilised by the MAPK pathway encode inflammatory mediators, suggesting that this kinase pathway plays a major role in the regulation of inflammation. The aim of this study was to determine if the MAPK pathway regulates the inflammatory response in human gestational tissues. Placenta and fetal membranes (n = 5) obtained from pregnant women undergoing Caesarean section before the onset of labour were exposed to LPS, and co-incubated in the absence or presence of 12.5, 25 and 50 μM U0126 (ERK 1/2 inhibitor), SB202190 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor). After 18 h incubation, tissues were collected and ERK 1/2, p38 MAPK, and JNK total and phosphorylated protein expression was assessed by ELISA and/or Western blotting. The incubation medium was collected and TNF-α, IL-1β, IL-6, IL-8, PGE2 and PGF2α release was quantified by ELISA. Treatment of placenta and fetal membranes with LPS activated all three MAPK proteins. Co-incubation with U0126, SP600125 and SB202190 significantly suppressed LPS-stimulated activation of ERK 1/2, JNK, and p38 MAPK, respectively. All cytokine and prostaglandin release was significantly suppressed by all concentrations of U0126. LPS-stimulated IL-6, TNF-α, PGE2 and PGF2α release was significantly suppressed by treatment with all concentrations of SB202190, whereas ILS-stimulated IL-1β release was only significantly inhibited in the presence of 50 μM SB202190 and there was no effect of SB202190 on LPS-stimulated IL-8 release. SP600125 significantly repressed LPS-stimulated release of IL-1β and TNF-α at all concentrations, whereas LPS-stimulated IL-6, PGE2 and PGF release were inhibited at 25 and 50 μM. In conclusion, the MAPK inhibitors used in this study demonstrated differential activity against a range of sequelae commonly associated with inflammation, supporting the therapeutic potential of MAPK inhibitors in pregnancy complications associated with an aberrant inflammatory response.
Keyword Erk 1/2
p38 MAPK
Jnk
Placenta
Fetal Membranes
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: UQ Centre for Clinical Research Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 34 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 34 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 16 Jul 2011, 01:28:30 EST by System User on behalf of UQ Centre for Clinical Research